Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting

Daratumumab (Dara), a multiple myeloma (MM) therapy, is an antibody against the surface receptor CD38, which is expressed not only on plasma cells but also on NK cells and monocytes. Correlative data have highlighted the immune-modulatory role of Dara, despite the paradoxical observation that Dara r...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Leukemia
Egile Nagusiak: Viola, Domenico, Dona, Ada, Caserta, Enrico, Troadec, Estelle, Besi, Francesca, McDonald, Tinisha, Ghoda, Lucy, Gunes, Emine Gulsen, Sanchez, James F, Khalife, Jihane, Martella, Marianna, Karanes, Chatchada, Htut, Myo, Wang, Xiuli, Rosenzweig, Michael, Chowdhury, Arnab, Sborov, Douglas, Miles, Rodney R, Yazaki, Paul J., Ebner, Todd, Hofmeister, Craig C., Forman, Stephen J, Rosen, Steven T, Marcucci, Guido, Shively, John, Keats, Jonathan J, Krishnan, Amrita, Pichiorri, Flavia
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7572537/
https://ncbi.nlm.nih.gov/pubmed/32296125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0810-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak